Newron Secures €38M for Game-Changing Schizophrenia Drug

MILAN, Italy & MORRISTOWN, N.J. – February 16, 2026 – Newron Pharmaceuticals has secured up to €38 million in a significant financing deal designed to propel its lead drug candidate, evenamide, through the final and most critical stage of clinical trials. The investment underscores growing confidence in a novel treatment that could represent a paradigm shift for millions of patients suffering from treatment-resistant schizophrenia (TRS), a debilitating condition for which new options are desperately needed.

A Strategic Infusion for a High-Stakes Trial

The financing is structured as a multi-tranche equity agreement with a group of new and existing European and Asian investors. The initial tranche provides up to €15 million, with two subsequent payments of €11 million and €12 million contingent on the progress and, ultimately, the positive outcome of evenamide's Phase III program, known as ENIGMA-TRS. This structure provides Newron with immediate capital while aligning investor interests with clinical success.

According to the company, this financial runway is crucial. It is expected to fund operations well beyond the highly anticipated 12-week data readout from the ENIGMA-TRS 1 and 2 pivotal studies, slated for the fourth quarter of this year.

"The investment by this group of existing and new shareholders is further validation of our development strategy for evenamide as the potential first add-on therapy in schizophrenia," said Roberto Galli, CFO of Newron, in a statement. He emphasized the drug's potential for the "vast majority of patients who are poorly responding or resistant to available treatment options."

Beyond Dopamine: A New Scientific Frontier

For decades, the treatment of schizophrenia has been dominated by drugs that primarily target the brain's dopamine system. While effective for many, this approach leaves a substantial portion—up to one-third—of patients with persistent and debilitating symptoms, leading to a diagnosis of TRS. These patients represent one of the most significant unmet needs in modern psychiatry.

Evenamide breaks from this tradition. It is a first-in-class, orally available compound with a unique mechanism of action. Instead of acting on dopamine receptors, it selectively modulates glutamate, another key neurotransmitter. By blocking specific voltage-gated sodium channels, evenamide normalizes aberrant glutamate release—a dysfunction believed to underlie TRS—without affecting the brain's normal baseline activity.

This novel approach has shown significant promise in earlier studies. A Phase II/III trial (Study 008A) met its primary endpoint, demonstrating statistically significant improvement in symptoms for patients who were not responding adequately to their current antipsychotic medication. Furthermore, a one-year extension study showed that these benefits not only persisted but increased over time, with patients experiencing a continuous reduction in symptoms and a high retention rate of nearly 75%, all while maintaining a favorable safety profile comparable to a placebo. This combination of increasing efficacy and strong tolerability is rare in the field of antipsychotics.

Tapping a Multi-Billion Dollar Market

The market for schizophrenia therapies is substantial, with estimates projecting it to exceed $13 billion by the early 2030s. However, the segment for TRS remains underserved. The current gold standard, clozapine, is effective but comes with significant side effect risks, including a rare but potentially fatal blood disorder, requiring intensive patient monitoring that limits its use.

Evenamide is being developed as an add-on therapy, meaning it could be prescribed alongside a patient's existing antipsychotic, including clozapine. This strategy could allow it to seamlessly integrate into current treatment regimens, offering a new layer of hope for patients who have exhausted other options. If successful, it would be the first therapy specifically designed to augment existing treatments by targeting the glutamatergic system.

The ENIGMA-TRS program is designed to prove this potential. It comprises two large-scale, international studies enrolling over 1,000 patients combined, evaluating evenamide's efficacy and safety as an add-on therapy over both short (12-week) and long-term (one-year) periods.

Global Partnerships and Fortified Intellectual Property

Newron is not navigating this high-stakes development alone. The company has forged key strategic partnerships that not only validate evenamide's potential but also de-risk its path to market. A landmark agreement with EA Pharma, a subsidiary of Japanese giant Eisai, covers the development and commercialization of evenamide in Japan and other key Asian territories. Similarly, a deal with Myung In Pharm secures its future in South Korea. These agreements provide Newron with upfront payments, milestone revenues, and shared development costs, showcasing strong international interest in the drug.

This commercial strategy is underpinned by a robust intellectual property portfolio. The European Patent Office recently granted a new patent for evenamide that extends its market exclusivity in the EU until 2044. This long-term protection is a critical asset, ensuring Newron can capitalize on its innovation for decades if the drug receives regulatory approval.

With fresh capital, a novel scientific approach, and a clear path through its pivotal Phase III trials, Newron is positioned at the forefront of a potential revolution in schizophrenia treatment. The entire biopharmaceutical community, along with countless patients and their families, will be watching closely as the company works towards its next major clinical milestone later this year.